echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Trend differentiation of pharmaceutical stocks small and medium cap pharmaceutical stocks fell sharply

    Trend differentiation of pharmaceutical stocks small and medium cap pharmaceutical stocks fell sharply

    • Last Update: 2017-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network pharmaceutical stock market] what's the trend of pharmaceutical stocks this year? It is observed that white horse stocks such as Hengrui Pharmaceutical Co., Ltd have reached new highs, and some small and medium-sized pharmaceutical stocks have fallen sharply Since May, industrial capital has responded, and more than 10 pharmaceutical companies have disclosed the announcement or plan of increasing their holdings (picture source: Baidu picture) last week (may 22-26) the market as a whole fluctuated upward Nearly 140 A-share companies disclosed research records of institutions, with a small increase on a month on month basis Last week, pharmaceutical companies received more attention, and 14 companies in the sector received research, including Yunnan Baiyao, Yixintang, and nine top biology and Boya biology that have not been "welcome" for a long time However, on the secondary market performance, the above-mentioned 14 companies fell more or rose less in the week Nine of them closed lower, with Changsheng biology, a big loser, down more than 14% on a weekly basis, and its share price once hit a new low The biggest gainer was Hejia shares, which rose more than 8% in the week This year, the trend of pharmaceutical stocks has split White horse stocks such as Hengrui Pharmaceutical Co., Ltd set new highs, and some small and medium-sized pharmaceutical stocks fell sharply Since May, industrial capital has responded, and more than 10 pharmaceutical companies have disclosed the announcement or plan of increasing their holdings Looking back at the research, for pharmaceutical stocks, institutions are concerned about the richness of product lines and market prospects, the company's R & D capabilities, as well as the expansion of new business areas Lizhu group is very popular with institutions Last week, it received two batches of institutions including e-fonda and Yihu investment During the investigation, the organization inquired about the sales of key varieties and potential varieties in detail According to reports, the growth of shenqifu injection of Lizhu group was stable in the first quarter of this year, with a year-on-year growth of sales revenue of 4% However, due to the implementation of low bid price in some provinces, the growth of sales side was slightly higher than that of income side In terms of other potential varieties, in the first quarter, the growth rate of hormone field of Lizhu group was about 19%, of which the growth rate of leuprorelin microsphere was more than 50%, and the growth rate of urofollicle stimulating hormone, urogonadotropin and chorionic gonadotropin was only one digit due to the high base last year The growth rate of eprazole enteric coated tablets was about 50%, and that of nerve growth factor was over 40% In addition, some double cross varieties began to make efforts in hospital sales, with an increase of speed, such as antiviral granules, with a 40% increase in the first quarter The organization also pays attention to the progress of Lizhu group's medical layout at this stage The company said that it is the only pharmaceutical listed company in China with in vitro diagnosis, antibody targeted drugs, national key hospital testing, pathology, clinical and marketing resources Since the registration of Lizhu gene testing technology Co., Ltd was completed in December last year, the medical industry chain layout of "Lizhu reagent + Lizhu mAb + Lizhu shengmei + Lizhu gene" has been preliminarily formed; in the future, we will actively seek domestic and foreign projects, and constantly enrich the medical industry layout through business cooperation and other ways In addition, many companies of biological preparations in the pharmaceutical sub sector have also attracted more attention, including Jiuqiang biology, Boya biology, Changchun hi tech, Changsheng biology, etc More than a year later, the top nine organisms were investigated again On May 23, nearly 30 institutions, including Xingshi investment and Harvest Fund, visited the company Jiuqiang biology is mainly engaged in the research, development, production and sales of biochemical diagnosis system In early May, it just announced that it plans to acquire 332.5 million yuan from Beijing meichuang Xinyue, the agent of German TECO, a hemagglutination diagnosis company When it comes to the hemagglutination market, the top nine think there is room for development According to reports, the domestic coagulation project started late Since 2000, the coagulation industry has increased greatly every year In hospitals, coagulation examination covers almost all clinical departments, while most hospitals in China still only carry out 4-8 items of coagulation, which is far from meeting the clinical needs In addition, Boya biology announced plans to transfer plasma from Danxia biology on the evening of May 22 Southwest Securities visited the company separately on May 23, and inquired about the company's allocation process, Danxia biological plasma inventory, expected profits after the successful allocation, etc And this research is also the research of the company's harvest this year Chongyang investment, Bank of China International and other institutions jointly investigated the growth biology on May 24, involving the competition of varicella vaccine, the progress of products under research and other issues of concern to the institution; in addition, Changchun hi tech, which was increased by 8 directors, supervisors and senior executives of the company in May, received China finance fund, Bank of China International and other institutions on May 24.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.